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Abstract
Brucellosis is a multi-system infectious disease that presents with various clinical man‐
ifestations and complications. Neurobrucellosis is an uncommon but serious presenta‐
tion of  brucellosis  that  can be seen in all  stages of  the disease.  Neurobrucellosis  is  a
focal complication of brucellosis affecting both central and peripheral nervous system
presenting  varieties  of  signs  and  symptoms.  The  most  reported  manifestations  are
meningitis  and meningoencephalitis.  It  is  a  rare  presentation of  brucellosis.  The  esti‐
mated  mean  incidence  of  neurobrucellosis  is  1.7%–10%.  The  incidence  is  equal  in
males  and  females.  Initial  clinical  manifestations  consisted  of  meningoencephalitis,
acute and subacute meningitis, intracranial hypertension, polyradiculoneuritis, cerebral
and subarachnoid hemorrhage, transverse myelitis,  lumbar epidural abscess with root
involvement,  and cranial  nerve  involvement.  Other  rare  manifestation includes  pseu‐
dotumor cerebri,  intracranial  granuloma,  sagittal  sinus  thrombosis,  spinal  arachnoidi‐
tis,  and intracranial vasculitis.  High index of suspicion, especially in endemic areas is
essential to prevent morbidity from this disease. Clinical suspicion and accurate evalu‐
ation of a patient's history is the most important clue in diagnosis and treatment. Neu‐
robrucellosis  can  be  diagnosed  by  isolation  of  microorganism  from  the  CSF  or
detection of antibodies in the CSF. The CSF pattern in neurobrucellosis can be helpful
for diagnosis; lymphocytic pleocytosis, increased protein, and decreased glucose levels
in the CSF are in favor of neurobrucellosis.  Imaging modalities, including CT scan or
magnetic  resonance  imaging,  may reveal  information  for  diagnosis.  Many laboratory
procedures  are  usually  employed  in  the  diagnosis  of  neurobrucellosis.  Even  though
the  culture  method  is  the  gold  standard,  growth  rate  is  low  and  time  consuming.
Coombs' test should be performed in both the CSF and serum. Different regimens are
usually  used  based  on  ceftriaxone,  doxycycline,  cotrimoxasole,  streptomycin,  and  ri‐
fampicin.  Treatment  with  intravenous  ceftriaxone  and  oral  rifampicin,  doxycycline,
and trimethoprim–sulfamethoxazole resulted in a good clinical response. Patients with
severe  and persistent  headache and other  neurologic  symptoms and signs  should be
considered for  neurobrucellosis  in  endemic regions.  Early diagnosis  and treatment  of
neurobrucellosis will be helpful in decreasing the sequelae of this complication.
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1. Introduction
Brucellosis is a common zoonotic infection worldwide and is caused by Brucella species.
Central nervous system (CNS) involvement is a serious complication of brucellosis with
different clinical presentation [1]. Neurobrucellosis is a focal complication of brucellosis
affecting both central and peripheral nervous system (PNS) presenting with a variety of signs
and symptoms [2]. Neurologic involvement due to brucellosis was reported in 1.7%–10% of
the patients with brucellosis [3, 4, 5]. Neurological complications of brucellosis are divided
into two groups. The first are those that have a direct effect of microorganism on the CNS and
PNS, and the second are those that have indirect effect of brucellosis on the CNS or PNS, e.g.,
toxic-febrile neurobrucellosis [6].
2. Clinical manifestations
Neurobrucellosis can affect any part of the nervous system and can mimic any neurological
disease [7]. The most reported manifestations of neurobrucellosis are meningitis and menin‐
goencephalitis [2]. Neurobrucellosis may also present as myelitis, myelopathy, stroke,
paraplegia, radiculoneuritis, intracerebral abscess, epidural abscess, intradural abscess,
demyelination, Guillain-Barré syndrome, polyneuritis, and cranial nerve involvement or any
combination of these manifestations [3, 8, 9, 10]. Neurobrucellosis affects the second, third,
sixth, seventh, and eighth cranial nerves. Involvement of the oculomotor nerves is a very rare
complication in neurobrucellosis [11]. Optic neuritis due to neurobrucellosis has been reported
[12]. Neurobrucellosis can cause hearing loss. It may affect the auditory pathway. Sensorineu‐
ral hearing loss can be seen due to brucellosis. Cochlear implantation may be successful for
treatment of patients with sensorineural hearing loss [13]. Neurobrucellosis may present rarely
with communicating hydrocephalus with symptoms of headaches, nausea, vomiting, gait
disturbance and signs of dysmmetry, ataxia, and sensorineural hearing loss [14]. Spastic
paraparesis and the sensorineural involvement are rare manifestations [8]. Solitary intracranial
mass lesions mimicking cerebral tumor are extremely rare presentations of neurobrucellosis
[15]. It may also present as leukoencephalopathy [16]. Cerebral venous sinus thrombosis due
to brucellosis is a rare form of stroke caused by thrombosis in venous sinuses of the brain [17].
Sagittal sinus thrombosis is one of the manifestations [18]. Neurobrucellosis is associated rarely
with demyelination. It may involve the corpus callosum [19]. Spinal epidural abscess due to
the Brucella species is usually associated with spondylodiscitis. Urgent surgical decompres‐
sion should be performed in cases with moderate to severe neurological deficits particularly
if progressive [20]. Quadriplegia and multiple brain abscesses have been reported as mani‐
festations of neurobrucellosis [21]. There are reports of intramedullary brucellar granuloma as
rare cases of neurobrucellosis. Nas et al. reported a patient presented with loss of strength of
four extremities. An intramedullary mass lesion was detected in the cervical level and brucellar
granuloma of the cervical spine was diagnosed finally [22]. In Asadipouya's study on neuro‐
brucellosis, headache, fever, neck rigidity, fatigue, altered mental status, speech disturbances,
nausea, and vomiting were the most common symptoms. Hearing loss, paraplegia, cerebellar
ataxia, diplopia, photophobia, blurred vision, abnormal behavior, hypoesthesia, low back
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pain, and right side weakness are categorized as less common clinical features [6]. An analytical
study on several publications on neurobrucellosis demonstrated that the most frequent
symptoms of neurobrucellosis are fever, headache, weight loss, sweating, and back pain; and
the most frequent signs of neurobrucellosis are meningeal irritation, confusion, hypoesthesia,
hepatomegaly, and splenomegaly. Crainial nerve involvement, polyneuropathy, polyradicul‐
opathy, paraplegia, and abscess formation may occur during neurobrucellosis. Symptom
duration may vary between one week and six months [23, 24]. Patients with neurobrucellosis
may present with neuropsychiatric signs and symptoms including aphasia, diplopia, hemi‐
paresis, facial paralysis, tremor, ataxia, depression, personality disorder, hallucinations,
agitation, behavioral disorders, muscle weakness, and disorientation [25, 26]. Shehata's study
demonstrated that CNS involvement (vascular stroke, meningeoencephalitis, and dementia)
was seen in 33% of patients and PNS involvement (polyneuropathy, radiculoapathy, and
polyradiculoneuropathy) was seen in 22% of patients. Depression was recorded in 29% of
patients. Patients with neurobrucellosis reported highly significant impairment in some
cognitive function measures (mental control, logical memory, visual reproduction) and higher
scores on depressive symptoms compared with controls [27]. Brucellosis may infect ventriculo-
peritoneal shunt [28]. The mean duration of symptoms before admission is 8 weeks (range: 1
week–4 months) [6]. In neurobrucellosis, CNS invasion by bacteria results in an inflammatory
disorder. During neurobrucellosis, migroglia and astrocytes may be involved. The results of
these involvements are production of pro-inflammatory cytokines that are harmful for CNS.
Matrix metalloproteinases (MMP) has been found in the inflammatory process of CNS. Pro-
inflammatory cytokines cause increased production of MMP. During neurobrucellosis,
astrogliosis occurs [29]. Inflammatory response elicited by Brucella in astrocytes would lead
to the production of MMP-9 and that mitogen-activated protein kinases may play a role in this
phenomenon. Mitogen-activated protein kinases inhibition may thus be considered as a
strategy to control inflammation and CNS damage in neurobrucellosis [30]. Brucella lipopro‐
teins could be key virulence factors in neurobrucellosis and that astrogliosis might contribute
to neurobrucellosis pathogenesis [31].
3. Complications
Recovery of neurobrucellosis may accompany with sequela. Paraparesis, dementia, sphincter
dysfunction, peripheral facial paralysis, and sensorineural hearing loss may occur [10, 25].
Communicating hydrocephalus has been reported as a complication of neurobrucellosis that
may need external ventricular drainage [32]. Mild sequelae, including aphasia, hearing loss,
and hemiparesis, may remain after successful treatment [33]. The mortality of neurobrucellosis
can be up to 0.5% with suitable antibiotics [24].
4. Diagnosis
Clinical suspicion and accurate evaluation of a patient's history is the most important clue in
the diagnosis and treatment of brucellosis [17]. Early detection and treatment is an important
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predictor of favorable outcome of neurobrucellosis [7]. Diagnosis requires a high index of
suspicion in patients from endemic areas. Diagnosis is often based on neurological symptoms,
serology, and suggestive brain imaging [34]. In patients with laboratory-confirmed brucellosis,
the neurobrucellosis may be diagnosed with one of these criteria: first, signs and symptoms of
neurobrucellosis include fever, headache, and cranial nerve palsies; second, CSF abnormality
compatible with brucellosis including CSF lymphocytic pleocytosis, low glucose, and high
protein levels of CSF detection of anti-Brucella antibodies in the CSF or isolation of Brucella
from the CSF; third, imaging abnormality compatible with brucellosis especially in CT scan
and MRI [25].
In a study on patients with neurobrucellosis, criteria for diagnosis was defined as: 1) neuro‐
brucellosis clinical manifestation; 2) CSF abnormality (lymphocytosis, decreased glucose,
increased protein); 3) positive anti-brucella antibody in the CSF or serum; 4) clinical response
to empirical therapy; and 5) no other diagnosis compatible with signs and symptoms [6]. The
sensitivity of tube agglutination in the CSF is 0.94, specificity 0.96, positive predictive value
0.94, and negative predictive value 0.96 [25].
In Erdem's study on 177 patients with neurobrucellosis mean values of the CSF, biochemical
test results were as follows: CSF leucocyte count=215, CSF protein=330 mg/dL, CSF/blood-
glucose ratio=0.35. The sensitivity of serum standard tube agglutination was 94%; CSF
standard tube agglutination was 78%. Blood culture was positive for brucellosis in 37% by
automated method and CSF culture was positive in 25% and 9% by automated and conven‐
tional CSF culture, respectively [35]. Another study showed the CSF WBC count to be between
6 cells/dl and 3600 cells/dl with mean count of 403 cells/dl. Most of the patients had CSF
lymphocyte predominance and some had CSF polymorphonuclear predominance. Elevated
CSF protein (>45 mg/dl) was detected in about 90% of the patients. CSF low glucose level (<40
mg/dl or CSF/Serum glucose ratio of <0.4) was seen in about half of the patients [6]. Yetkin's
study demonstrated that the mean count of CSF WBC was 244 with high CSF protein level in
all patients and low CSF glucose level in half of the patients [23]. Brucella bacteria may be
isolated from CSF in only 15% of the patients. Brucella tube agglutination with Coombs test
in the CSF is sensitive and specific [25]. Serum agglutination test is often used for screening
and as a complement fixation test for confirmatory tests. Enzyme-linked immunosorbant assay
(ELISA) for brucella is more sensitive and specific than other serological tests and it may
replace other serological tests. ELISA may detect antibodies against brucella in the serum and
CSF. A patient with neurobrucellosis may have negative serological markers of brucellosis in
the CSF and serum. Serum anti-brucella immunoglobulin G (IgG) and immunoglobulin M
(IgM) antibody may be checked using the ELISA method for patients who had negative
Coomb's Wright agglutination tests results [6]. Adenosine deaminase (ADA) activity in the
CSF of patients with brucella meningitis can be used for diagnosis. CSF ADA activity with cut-
off value of 12.5 IU/L has a sensitivity of 92% and specificity of 88% for diagnosis of brucella
meningitis [36]. When cerebrospinal fluid culture is negative, PCR may be an optimal alter‐
native tool for an immediate and accurate diagnosis [37]. Imaging findings of neurobrucellosis
is divided into four categories: (1) normal, (2) inflammation (recognized by granulomas,
abnormal enhancement of the meninges, perivascular space, or lumbar nerve roots), (3) white
matter changes, and (4) vascular changes [38]. Infarct in the anterior limb of the left internal
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capsule and putamenal infarctions has been reported due to brucellosis. The diagnosis of
neurobrucellosis can be considered despite negative CSF culture and serology based on clinical
response and resolution of CSF abnormality with anti-brucella treatment [6]. Tekin-Koruk
reported a seronegative neurobrucellosis case with depression and diplopia. Results of
agglutination tests for Brucella both in the serum and CSF were negative. Diagnosis was made
only by positive culture of Brucella mellitensis with inoculation of the patient's cerebrospinal
fluid in a BACTEC 9050 System [39].
5. Treatment
Neurobrucellosis is a treatable disease with a favorable outcome. Doxycycline, rifampicin,
ceftriaxone, trimethoprim sulfamethoxazole, ciprofloxacin, and streptomycin have been found
effective in neurobrucellosis [6]. An important challenge in treatment of brucellar meningitis
or meningoencephalitis is that patients should be treated with oral antibiotics or whether an
intravenous extended-spectrum cephalosporin, such as ceftriaxone, which does not accumu‐
late in phagocytes, should be added to the regimen. Several different protocols have been used
for treatment. Ceftriaxone, rifampin, and doxycycline or trimethoprim-sulfamethoxazole,
rifampin, and doxycycline have been used for treatment. Ceftriaxone-based regimens are more
successful and require shorter therapy than the oral treatment protocol [40]. Treatment
protocol in Karsen's study consisted of ceftriaxone, rifampicin, and doxycyline for a period of
four weeks, followed by rifampicin and doxycyline for an additional four weeks [26]. Duration
of treatment will depend on the patient's condition. If rapid improvement occurs, we may
shorten the duration of antibiotic therapy to 12 weeks and continue their treatment by clinical
assessment. In the study by Bodur, all patients received antibiotic therapy with ceftriaxone,
rifampicin, and doxycycline initially and after one month they were continued with rifampicin
and doxycycline up to four months. Oral Doxycycline and rifampin with intravenously
ceftriaxone are the most common antibiotics in the treatment of neurobrucellosis [6]. Gul's
study demonstrated that parenteral ceftriaxone should be used as an initial alternative in the
management of neurobrucellosis [41]. Duration of treatment varies in different studies ranging
from several weeks to several months. In Ceran's study, duration of treatment varied between
3 and 12 months according to the CSF response [33]. According to Gul's study, it is recom‐
mended that the duration of therapy should be a minimum of six months with suitable
antibiotics, although the therapy should be individualized [41]. In contrast, in Asasipouya's
study in Iran, duration of treatment was as short as eight weeks in about half of the patients.
Short course treatment in neurobrucellosis is possible in patients with meningoencephalitis
who do not have any focal neurologic deficit or have minimal deficit. Other patients need
treatment for a long duration according to neurologic manifestations [6].
6. Conclusion
Patients with severe and persistent headache and other neurologic symptoms and signs should
be considered for neurobrucellosis in endemic regions [25]. It should be included in differential
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diagnosis for any patient presenting with central or peripheral neurological manifestations
especially in endemic areas [7]. With early diagnosis and treatment, neurobrucellosis has a
good outcome with no or minimal neurologic complications. The duration of disease and the
time between starting symptoms and starting antibiotic influences the prognosis [6].
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